<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - FDA Recommends Approval of Peanut Allergy Medicine
Image Overlay - FDA Recommends Approval of Peanut Allergy Medicine

FDA Recommends Approval of Peanut Allergy Medicine

FDA Recommends Approval of Peanut Allergy Medicine

Aimmune has developed a new oral immunotherapy designed to enable peanut allergy sufferers to avoid serious allergic reactions if exposed to minor quantities of peanut protein. Palforzia (previously AR101) is a peanut-derived biologic that delivers a daily dose of peanut protein with a consistent protein profile, analyzed to ensure reliable major allergen content. Regular consumption of Palforzia is intended to reduce allergic reactions. There are no treatments for peanut allergy approved by the U.S. Food and Drug Administration (FDA), but that may soon change. Yourway keeps the supply chain moving. We are able to seamlessly manage any inventory through our easy-to-use client portal.

Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat
Come chat with us!
Hello! How can I help you?